首页 > 最新文献

Annals of Thoracic and Cardiovascular Surgery最新文献

英文 中文
Prognostic Impact of Pretreatment Serum CYFRA Status in 1047 Patients with Esophageal Squamous Cell Carcinoma Who Underwent Radical Resection: A Japan Esophageal Society Promotion Research. 1047例食管鳞癌根治性切除术患者血清预处理CYFRA水平对预后的影响:一项日本食管学会促进研究
IF 1.3 4区 医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2022-06-20 Epub Date: 2022-06-17 DOI: 10.5761/atcs.oa.21-00195
Nobuki Ishioka, Takashi Suzuki, Satoshi Yajima, Kentaro Murakami, Yu Ohkura, Takashi Fukuda, Koichi Yagi, Akihiko Okamura, Isamu Hoshino, Chikara Kunisaki, Yasuaki Nakajima, Kosuke Narumiya, Ryo Ogawa, Hideaki Shimada

Purpose: The prognostic significance of pretreatment serum C-terminus of cytokeratin 19 (CYFRA21-1, CYFRA) status was evaluated in the patients with surgically treated esophageal squamous cell carcinoma.

Methods: A total of 1047 patients with surgically treated esophageal cancer were enrolled in a multi-institutional study promoted by the Japanese Esophageal Society. This study included an up-front surgery group (n = 412), a neoadjuvant chemotherapy (NAC) group (n = 486), and a neoadjuvant chemoradiation/radiation therapy (NACRT/RT) group (n = 149). The pretreatment CYFRA status was analyzed to assess prognostic significance using multivariate analysis according to treatment modalities.

Results: The CYFRA-positive group was significantly associated with deep tumor. Univariate analysis showed that the overall survival of the CYFRA-positive group was significantly worse than that of the CYFRA-negative group, but the difference was not significant in the multivariate analysis. CYFRA was an independent risk factor for poor prognosis just in the NACRT/RT group.

Conclusions: The CYFRA-positive group was associated with deep tumor and poor survival. Pretreatment CYFRA was not an independent risk factor for poor prognosis in the up-front surgery group or NAC group. It was an independent risk factor for poor prognosis just in the NACRT/RT group.

目的:探讨术前血清c -末端细胞角蛋白19 (CYFRA21-1, CYFRA)水平对食管鳞癌患者预后的影响。方法:共有1047例手术治疗的食管癌患者参加了一项由日本食管学会推动的多机构研究。本研究包括前期手术组(n = 412)、新辅助化疗组(n = 486)和新辅助放化疗/放疗组(n = 149)。根据治疗方式,采用多因素分析分析预处理CYFRA状态,评估预后意义。结果:cyfr阳性组与深部肿瘤有显著相关性。单因素分析显示,cyfr -阳性组的总生存率明显差于cyfr -阴性组,但多因素分析差异无统计学意义。仅在NACRT/RT组中,CYFRA是预后不良的独立危险因素。结论:cyfr阳性组与深部肿瘤相关,生存期较差。预处理CYFRA在前期手术组和NAC组均不是预后不良的独立危险因素。仅在NACRT/RT组中,它是预后不良的独立危险因素。
{"title":"Prognostic Impact of Pretreatment Serum CYFRA Status in 1047 Patients with Esophageal Squamous Cell Carcinoma Who Underwent Radical Resection: A Japan Esophageal Society Promotion Research.","authors":"Nobuki Ishioka,&nbsp;Takashi Suzuki,&nbsp;Satoshi Yajima,&nbsp;Kentaro Murakami,&nbsp;Yu Ohkura,&nbsp;Takashi Fukuda,&nbsp;Koichi Yagi,&nbsp;Akihiko Okamura,&nbsp;Isamu Hoshino,&nbsp;Chikara Kunisaki,&nbsp;Yasuaki Nakajima,&nbsp;Kosuke Narumiya,&nbsp;Ryo Ogawa,&nbsp;Hideaki Shimada","doi":"10.5761/atcs.oa.21-00195","DOIUrl":"https://doi.org/10.5761/atcs.oa.21-00195","url":null,"abstract":"<p><strong>Purpose: </strong>The prognostic significance of pretreatment serum C-terminus of cytokeratin 19 (CYFRA21-1, CYFRA) status was evaluated in the patients with surgically treated esophageal squamous cell carcinoma.</p><p><strong>Methods: </strong>A total of 1047 patients with surgically treated esophageal cancer were enrolled in a multi-institutional study promoted by the Japanese Esophageal Society. This study included an up-front surgery group (n = 412), a neoadjuvant chemotherapy (NAC) group (n = 486), and a neoadjuvant chemoradiation/radiation therapy (NACRT/RT) group (n = 149). The pretreatment CYFRA status was analyzed to assess prognostic significance using multivariate analysis according to treatment modalities.</p><p><strong>Results: </strong>The CYFRA-positive group was significantly associated with deep tumor. Univariate analysis showed that the overall survival of the CYFRA-positive group was significantly worse than that of the CYFRA-negative group, but the difference was not significant in the multivariate analysis. CYFRA was an independent risk factor for poor prognosis just in the NACRT/RT group.</p><p><strong>Conclusions: </strong>The CYFRA-positive group was associated with deep tumor and poor survival. Pretreatment CYFRA was not an independent risk factor for poor prognosis in the up-front surgery group or NAC group. It was an independent risk factor for poor prognosis just in the NACRT/RT group.</p>","PeriodicalId":8037,"journal":{"name":"Annals of Thoracic and Cardiovascular Surgery","volume":"28 3","pages":"163-170"},"PeriodicalIF":1.3,"publicationDate":"2022-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d6/11/atcs-28-163.PMC9209890.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39551703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
IgG4-Related Lung Disease Exhibiting the Invasion into the Diaphragm: A Case Report. igg4相关肺部疾病侵犯横膈膜1例
IF 1.3 4区 医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2022-06-20 Epub Date: 2020-02-27 DOI: 10.5761/atcs.cr.19-00244
Yuki Ono, Gouji Toyokawa, Tetsuzo Tagawa, Kayo Ijichi, Yoshinao Oda, Masaki Mori

Immunoglobulin G4-related disease (IgG4-RD) is a fibroinflammatory condition which involves various organs. This is a very rare case of IgG4-related lung disease (IgG4-RLD) with the invasion into diaphragm. The patient was a 71-year-old man with a long-term exposure to asbestos who had a mass shadow in the left lower lung lobe, which was suspected to invade the left diaphragm on computed tomography (CT). Positron emission tomography (PET)/CT also presented an avid intake of fluorodeoxyglucose in the mass, which suspected lung cancer. Although bronchoscopic biopsy could not lead to the definite diagnosis, we performed left lower lobectomy combined with the resection of left diaphragm. The specimen showed the features of IgG4-RLD on pathology: the vein stenosis and fibrosis around the vein, the infiltration of IgG4-positive cells, and IgG cells to IgG4 cells ratio of 40%. Furthermore, there were inflammatory cells infiltrating to the diaphragm.

免疫球蛋白g4相关疾病(IgG4-RD)是一种累及多器官的纤维炎性疾病。这是一个非常罕见的igg4相关肺部疾病(IgG4-RLD)侵犯膈肌的病例。患者为71岁男性,长期接触石棉,左下肺叶肿块影,CT检查怀疑侵犯左膈。正电子发射断层扫描(PET)/CT也显示肿块大量摄入氟脱氧葡萄糖,怀疑为肺癌。虽然支气管镜活检不能明确诊断,但我们行左下肺叶切除联合左膈切除术。标本病理表现为IgG4- rld特征:静脉狭窄,静脉周围纤维化,IgG4阳性细胞浸润,IgG细胞与IgG4细胞的比例为40%。此外,有炎症细胞浸润到膈肌。
{"title":"IgG4-Related Lung Disease Exhibiting the Invasion into the Diaphragm: A Case Report.","authors":"Yuki Ono,&nbsp;Gouji Toyokawa,&nbsp;Tetsuzo Tagawa,&nbsp;Kayo Ijichi,&nbsp;Yoshinao Oda,&nbsp;Masaki Mori","doi":"10.5761/atcs.cr.19-00244","DOIUrl":"https://doi.org/10.5761/atcs.cr.19-00244","url":null,"abstract":"<p><p>Immunoglobulin G4-related disease (IgG4-RD) is a fibroinflammatory condition which involves various organs. This is a very rare case of IgG4-related lung disease (IgG4-RLD) with the invasion into diaphragm. The patient was a 71-year-old man with a long-term exposure to asbestos who had a mass shadow in the left lower lung lobe, which was suspected to invade the left diaphragm on computed tomography (CT). Positron emission tomography (PET)/CT also presented an avid intake of fluorodeoxyglucose in the mass, which suspected lung cancer. Although bronchoscopic biopsy could not lead to the definite diagnosis, we performed left lower lobectomy combined with the resection of left diaphragm. The specimen showed the features of IgG4-RLD on pathology: the vein stenosis and fibrosis around the vein, the infiltration of IgG4-positive cells, and IgG cells to IgG4 cells ratio of 40%. Furthermore, there were inflammatory cells infiltrating to the diaphragm.</p>","PeriodicalId":8037,"journal":{"name":"Annals of Thoracic and Cardiovascular Surgery","volume":"28 3","pages":"223-226"},"PeriodicalIF":1.3,"publicationDate":"2022-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5761/atcs.cr.19-00244","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37679707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
A Surgical Case of Bronchial Artery Aneurysm Connecting to a Pulmonary Artery and Vein Complicated by Racemose Hemangioma. 支气管动脉瘤与肺静脉连接并发总状血管瘤1例。
IF 1.3 4区 医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2022-06-20 Epub Date: 2020-05-18 DOI: 10.5761/atcs.cr.19-00302
Tomoki Nishida, Naoko Isogai, Rai Shimoyama, Jun Kawachi, Toshitaka Tsukiyama, Ken-Ichiro Noguchi, Ryuta Fukai

We report a surgical case of bronchial artery aneurysm (BAA) that directly connected to a pulmonary artery and a pulmonary vein through an abnormal vessel. It was complicated by racemose hemangioma. This is a rare vascular malformation. An 82-year-old female had a large BAA that was found incidentally. First, we consider treating the BAA with embolization by interventional radiology (IVR). However, because of strong meandering of the bronchial artery, we could not advance a microcatheter into the BAA. Therefore, a surgical operation was performed through a standard posterior lateral thoracotomy. The BAA was located between the upper and lower lobes and directly connected to the pulmonary artery. Some bronchial artery branches that provided inflow to the aneurysm were ligated, and the abnormal vessel that connected the BAA to the upper pulmonary vein was ligated easily. A fistula between the BAA and pulmonary artery was sutured by the cardiovascular surgeon using an artificial cardiopulmonary device, with permissive stenosis of A2b (ascending A2).

我们报告一例支气管动脉瘤(BAA)通过异常血管直接连接肺动脉和肺静脉的手术病例。合并有总状血管瘤。这是一种罕见的血管畸形。一名82岁的女性偶然发现了一个很大的BAA。首先,我们考虑通过介入放射学(IVR)栓塞治疗BAA。然而,由于支气管动脉曲流较强,我们无法将微导管推进BAA。因此,我们通过标准的后外侧开胸手术进行手术。BAA位于上下叶之间,与肺动脉直接相连。结扎部分为动脉瘤提供流入的支气管动脉分支,连接BAA与上肺静脉的异常血管容易结扎。心血管外科医生使用人工心肺装置缝合BAA和肺动脉之间的瘘管,允许A2b狭窄(上升A2)。
{"title":"A Surgical Case of Bronchial Artery Aneurysm Connecting to a Pulmonary Artery and Vein Complicated by Racemose Hemangioma.","authors":"Tomoki Nishida,&nbsp;Naoko Isogai,&nbsp;Rai Shimoyama,&nbsp;Jun Kawachi,&nbsp;Toshitaka Tsukiyama,&nbsp;Ken-Ichiro Noguchi,&nbsp;Ryuta Fukai","doi":"10.5761/atcs.cr.19-00302","DOIUrl":"https://doi.org/10.5761/atcs.cr.19-00302","url":null,"abstract":"<p><p>We report a surgical case of bronchial artery aneurysm (BAA) that directly connected to a pulmonary artery and a pulmonary vein through an abnormal vessel. It was complicated by racemose hemangioma. This is a rare vascular malformation. An 82-year-old female had a large BAA that was found incidentally. First, we consider treating the BAA with embolization by interventional radiology (IVR). However, because of strong meandering of the bronchial artery, we could not advance a microcatheter into the BAA. Therefore, a surgical operation was performed through a standard posterior lateral thoracotomy. The BAA was located between the upper and lower lobes and directly connected to the pulmonary artery. Some bronchial artery branches that provided inflow to the aneurysm were ligated, and the abnormal vessel that connected the BAA to the upper pulmonary vein was ligated easily. A fistula between the BAA and pulmonary artery was sutured by the cardiovascular surgeon using an artificial cardiopulmonary device, with permissive stenosis of A2b (ascending A2).</p>","PeriodicalId":8037,"journal":{"name":"Annals of Thoracic and Cardiovascular Surgery","volume":"28 3","pages":"227-231"},"PeriodicalIF":1.3,"publicationDate":"2022-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5761/atcs.cr.19-00302","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37945684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hemoadsorption of Rivaroxaban and Ticagrelor during Acute Type A Aortic Dissection Operations. 利伐沙班和替格瑞洛在急性A型主动脉夹层手术中的血液吸附作用。
IF 1.3 4区 医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2022-06-20 Epub Date: 2022-01-20 DOI: 10.5761/atcs.oa.21-00154
Kambiz Hassan, Tabea Brüning, Michael Caspary, Peter Wohlmuth, Holger Pioch, Michael Schmoeckel, Stephan Geidel

Objective: To analyze the results of hemoadsorption in patients with cardiac surgery to thoracic aortic surgery, who had been loaded beforehand with either Factor Xa inhibitor rivaroxaban or P2Y12 receptor antagonist ticagrelor.

Methods: We investigated 21 of 171 consecutive patients (median age 71 [interquartile range 62, 76] years) who underwent emergency cardiac operations for acute type A aortic dissection between 2014 and 2020. These patients were pretreated with rivaroxaban (n = 9) or ticagrelor (n = 12). In ten of 21 cases (since 2017), we installed a hemoadsorber into the heart-lung machine and compared the results to eleven patients done without hemoadsorber before that time.

Results: The operation time was significantly shorter in the adsorber group (286 ± 40 min vs. 348 ± 79 min; p = 0.045). The postoperative 24-hour drainage volume was significantly lower after adsorption (p <0.001; 482 ± 122 ml vs. 907 ± 427 ml) and no rethoracotomy had to be performed (compared to two rethoracotomies [18.9%] among patients without adsorber use). Also, patients without hemoadsorption required significantly more platelet transfusions (p = 0.049).

Conclusions: In patients with acute type A aortic dissection who were pretreated with rivaroxaban and ticagrelor, the intraoperative use of CytoSorb hemoadsorption during cardiopulmonary bypass is reported for the first time. The method was found to be effective to prevent from bleeding and to improve the outcome in aortic dissection.

目的:分析心脏手术至胸主动脉手术患者在术前使用Xa因子抑制剂利伐沙班或P2Y12受体拮抗剂替格瑞洛时血液吸附的结果。方法:我们调查了2014年至2020年期间因急性A型主动脉夹层接受紧急心脏手术的171例患者中的21例(中位年龄71岁[四分位数间距62,76]岁)。这些患者接受利伐沙班(n = 9)或替格瑞洛(n = 12)预处理。在21例患者中(自2017年以来),有10例患者在心肺机中安装了吸附剂,并将结果与此前未使用吸附剂的11例患者进行了比较。结果:吸附剂组手术时间明显缩短(286±40 min vs. 348±79 min);P = 0.045)。结论:在利伐沙班联合替格瑞洛预处理的急性A型主动脉夹层患者中,首次报道了体外循环术中使用CytoSorb血液吸附的情况。结果表明,该方法可有效防止主动脉夹层出血,改善预后。
{"title":"Hemoadsorption of Rivaroxaban and Ticagrelor during Acute Type A Aortic Dissection Operations.","authors":"Kambiz Hassan,&nbsp;Tabea Brüning,&nbsp;Michael Caspary,&nbsp;Peter Wohlmuth,&nbsp;Holger Pioch,&nbsp;Michael Schmoeckel,&nbsp;Stephan Geidel","doi":"10.5761/atcs.oa.21-00154","DOIUrl":"https://doi.org/10.5761/atcs.oa.21-00154","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the results of hemoadsorption in patients with cardiac surgery to thoracic aortic surgery, who had been loaded beforehand with either Factor Xa inhibitor rivaroxaban or P2Y12 receptor antagonist ticagrelor.</p><p><strong>Methods: </strong>We investigated 21 of 171 consecutive patients (median age 71 [interquartile range 62, 76] years) who underwent emergency cardiac operations for acute type A aortic dissection between 2014 and 2020. These patients were pretreated with rivaroxaban (n = 9) or ticagrelor (n = 12). In ten of 21 cases (since 2017), we installed a hemoadsorber into the heart-lung machine and compared the results to eleven patients done without hemoadsorber before that time.</p><p><strong>Results: </strong>The operation time was significantly shorter in the adsorber group (286 ± 40 min vs. 348 ± 79 min; p = 0.045). The postoperative 24-hour drainage volume was significantly lower after adsorption (p <0.001; 482 ± 122 ml vs. 907 ± 427 ml) and no rethoracotomy had to be performed (compared to two rethoracotomies [18.9%] among patients without adsorber use). Also, patients without hemoadsorption required significantly more platelet transfusions (p = 0.049).</p><p><strong>Conclusions: </strong>In patients with acute type A aortic dissection who were pretreated with rivaroxaban and ticagrelor, the intraoperative use of CytoSorb hemoadsorption during cardiopulmonary bypass is reported for the first time. The method was found to be effective to prevent from bleeding and to improve the outcome in aortic dissection.</p>","PeriodicalId":8037,"journal":{"name":"Annals of Thoracic and Cardiovascular Surgery","volume":"28 3","pages":"186-192"},"PeriodicalIF":1.3,"publicationDate":"2022-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/67/2e/atcs-28-186.PMC9209888.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39923425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
Early and Mid-Term Outcomes of Open versus Endovascular Left Subclavian Artery Debranching for Thoracic Aortic Diseases. 胸主动脉疾病左锁骨下动脉切开与血管内分离的早期和中期结果
IF 1.3 4区 医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2022-06-20 Epub Date: 2021-12-22 DOI: 10.5761/atcs.oa.21-00206
Philip Dueppers, Lorenz Meuli, Benedikt Reutersberg, Michael Hofmann, Florian Messmer, Alexander Zimmermann

Purpose: To compare open versus endovascular left subclavian artery debranching for thoracic endovascular aortic repair of thoracic aortic pathologies.

Methods: This is a retrospective study of patients receiving left subclavian artery debranching in our institution from October 2009 to January 2020. The primary outcome was freedom from aortic reintervention. Secondary outcomes were type I endoleaks, left subclavian artery (LSA) debranching failure, stroke, technical or clinical success, procedure-related reintervention, as well as 30-day or overall all-cause and aorta-related mortality.

Results: Forty-eight patients received parallel graft-based (n = 24, ENDO; median age 75 years [70-80 years]) or open (n = 24, OPEN; median age 71 years [59-75 years]) debranching for type B aortic dissection (n = 25), degenerative aneurysm (n = 12), type IA endoleak (n = 6), suture-associated (n = 3) or ostial LSA aneurysm (n = 1), or penetrating aortic ulcer (n = 1). The median follow-up was 36 months (13-61 months). After 16 months, aortic reintervention-free survival in groups OPEN and ENDO was 91% (95% confidence interval [CI]: 79 to 100%) and 86% (73 to 100%) (p = 0.71), respectively. After 36 months, all-cause survival in groups OPEN and ENDO was 74% (95% CI: 55 to 99%) and 79% (95% CI: 64 to 97%) (p = 0.74), respectively; freedom from aorta-related mortality was 81% (95% CI: 62 to 100%) and 91% (95% CI: 80 to 100%) (p = 0.78), respectively. Group OPEN presented less type I endoleaks (OPEN/ENDO = 3/19, p <0.001) and higher technical (OPEN/ENDO = 81/36%, p = 0.003) and clinical success rates (OPEN/ENDO = 67/36%, p = 0.047). No statistical differences were found for other outcomes.

Conclusion: Both strategies achieved comparable reintervention and mortality rates, but open debranching should be preferred due to its higher technical and clinical success and less type I endoleaks.

目的:比较开放与血管内左锁骨下动脉去分支在胸主动脉病变的血管内主动脉修复中的应用。方法:回顾性研究2009年10月至2020年1月在我院接受左锁骨下动脉去分支手术的患者。主要结局是主动脉再介入的自由。次要结局是I型内漏、左锁骨下动脉(LSA)去分支失败、中风、技术或临床成功、手术相关的再干预,以及30天或总体全因死亡率和主动脉相关死亡率。结果:48例患者接受平行移植(n = 24, ENDO;中位年龄75岁[70-80岁])或open (n = 24, open;中位年龄71岁[59-75岁]),因B型主动脉夹层(n = 25)、退行性动脉瘤(n = 12)、IA型内漏(n = 6)、缝合线相关(n = 3)或口部LSA动脉瘤(n = 1)或穿透性主动脉溃疡(n = 1)进行去分支手术。中位随访时间为36个月(13-61个月)。16个月后,OPEN组和ENDO组无主动脉再介入生存率分别为91%(95%可信区间[CI]: 79 ~ 100%)和86% (73 ~ 100%)(p = 0.71)。36个月后,OPEN组和ENDO组的全因生存率分别为74% (95% CI: 55 ~ 99%)和79% (95% CI: 64 ~ 97%) (p = 0.74);无主动脉相关死亡率分别为81% (95% CI: 62 ~ 100%)和91% (95% CI: 80 ~ 100%) (p = 0.78)。OPEN组出现较少I型内漏(OPEN/ENDO = 3/19, p)。结论:两种策略的再干预率和死亡率相当,但开放式去分支术因其较高的技术和临床成功率以及较少的I型内漏而应首选。
{"title":"Early and Mid-Term Outcomes of Open versus Endovascular Left Subclavian Artery Debranching for Thoracic Aortic Diseases.","authors":"Philip Dueppers,&nbsp;Lorenz Meuli,&nbsp;Benedikt Reutersberg,&nbsp;Michael Hofmann,&nbsp;Florian Messmer,&nbsp;Alexander Zimmermann","doi":"10.5761/atcs.oa.21-00206","DOIUrl":"https://doi.org/10.5761/atcs.oa.21-00206","url":null,"abstract":"<p><strong>Purpose: </strong>To compare open versus endovascular left subclavian artery debranching for thoracic endovascular aortic repair of thoracic aortic pathologies.</p><p><strong>Methods: </strong>This is a retrospective study of patients receiving left subclavian artery debranching in our institution from October 2009 to January 2020. The primary outcome was freedom from aortic reintervention. Secondary outcomes were type I endoleaks, left subclavian artery (LSA) debranching failure, stroke, technical or clinical success, procedure-related reintervention, as well as 30-day or overall all-cause and aorta-related mortality.</p><p><strong>Results: </strong>Forty-eight patients received parallel graft-based (n = 24, ENDO; median age 75 years [70-80 years]) or open (n = 24, OPEN; median age 71 years [59-75 years]) debranching for type B aortic dissection (n = 25), degenerative aneurysm (n = 12), type IA endoleak (n = 6), suture-associated (n = 3) or ostial LSA aneurysm (n = 1), or penetrating aortic ulcer (n = 1). The median follow-up was 36 months (13-61 months). After 16 months, aortic reintervention-free survival in groups OPEN and ENDO was 91% (95% confidence interval [CI]: 79 to 100%) and 86% (73 to 100%) (p = 0.71), respectively. After 36 months, all-cause survival in groups OPEN and ENDO was 74% (95% CI: 55 to 99%) and 79% (95% CI: 64 to 97%) (p = 0.74), respectively; freedom from aorta-related mortality was 81% (95% CI: 62 to 100%) and 91% (95% CI: 80 to 100%) (p = 0.78), respectively. Group OPEN presented less type I endoleaks (OPEN/ENDO = 3/19, p <0.001) and higher technical (OPEN/ENDO = 81/36%, p = 0.003) and clinical success rates (OPEN/ENDO = 67/36%, p = 0.047). No statistical differences were found for other outcomes.</p><p><strong>Conclusion: </strong>Both strategies achieved comparable reintervention and mortality rates, but open debranching should be preferred due to its higher technical and clinical success and less type I endoleaks.</p>","PeriodicalId":8037,"journal":{"name":"Annals of Thoracic and Cardiovascular Surgery","volume":"28 3","pages":"193-203"},"PeriodicalIF":1.3,"publicationDate":"2022-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cf/d0/atcs-28-193.PMC9209886.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39747603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Concomitant Mitral Regurgitation in Patients Undergoing Surgical Aortic Valve Replacement for Aortic Stenosis: A Systematic Review. 主动脉瓣狭窄手术置换术患者并发二尖瓣返流:一项系统综述。
IF 1.3 4区 医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2022-06-20 Epub Date: 2022-02-09 DOI: 10.5761/atcs.oa.21-00170
Francis P Cheung, Cheng He, Philippa R Eaton, Jim Dimitriou, Andrew E Newcomb
Background: Concomitant mitral regurgitation (MR) is frequently seen in patients undergoing surgical aortic valve replacement (AVR) for severe aortic stenosis (AS). When the severity of MR is moderate or less, the decision to undertake simultaneous mitral valve intervention can be challenging. Methods: A systematic search of Medline, PubMed (NCBI), Embase and Cochrane Library was conducted to qualitatively assess the current evidence for concomitant mitral valve intervention for MR in patients with AS undergoing AVR. The primary outcome for this systematic review was the postoperative change in the severity of MR and other outcomes of interest included factors that predict improvement or persistence of MR and long-term impacts of residual MR. Results: A total of 17 studies were included. The percentage of patients demonstrating improvement in MR severity following AVR ranged from 17.2% to 72%; the studies that exclusively included patients with moderate functional MR and reported longer term echocardiographic follow-up of greater than 12 months demonstrated an improvement in MR severity of 45% to 72%. Conclusion: This systematic review demonstrates that a proportion of patients can exhibit an improvement in MR following isolated surgical AVR, but whether this confers any long-term morbidity and mortality benefit remains unclear.
背景:合并二尖瓣反流(MR)在严重主动脉瓣狭窄(AS)的手术主动脉瓣置换术(AVR)患者中很常见。当MR的严重程度为中度或更轻时,同时进行二尖瓣介入治疗的决定可能具有挑战性。方法:系统检索Medline、PubMed (NCBI)、Embase和Cochrane图书馆,定性评估AS行AVR患者合并二尖瓣干预MR的现有证据。本系统评价的主要结果是术后MR严重程度的变化,其他感兴趣的结果包括预测MR改善或持续以及残余MR的长期影响的因素。结果:共纳入17项研究。AVR后MR严重程度改善的患者比例从17.2%到72%不等;专门纳入中度功能性MR患者的研究,并报告了超过12个月的长期超声心动图随访,结果显示MR严重程度改善了45%至72%。结论:本系统综述表明,部分患者在孤立性手术AVR后MR改善,但这是否会带来任何长期发病率和死亡率的益处尚不清楚。
{"title":"Concomitant Mitral Regurgitation in Patients Undergoing Surgical Aortic Valve Replacement for Aortic Stenosis: A Systematic Review.","authors":"Francis P Cheung,&nbsp;Cheng He,&nbsp;Philippa R Eaton,&nbsp;Jim Dimitriou,&nbsp;Andrew E Newcomb","doi":"10.5761/atcs.oa.21-00170","DOIUrl":"https://doi.org/10.5761/atcs.oa.21-00170","url":null,"abstract":"Background: Concomitant mitral regurgitation (MR) is frequently seen in patients undergoing surgical aortic valve replacement (AVR) for severe aortic stenosis (AS). When the severity of MR is moderate or less, the decision to undertake simultaneous mitral valve intervention can be challenging. Methods: A systematic search of Medline, PubMed (NCBI), Embase and Cochrane Library was conducted to qualitatively assess the current evidence for concomitant mitral valve intervention for MR in patients with AS undergoing AVR. The primary outcome for this systematic review was the postoperative change in the severity of MR and other outcomes of interest included factors that predict improvement or persistence of MR and long-term impacts of residual MR. Results: A total of 17 studies were included. The percentage of patients demonstrating improvement in MR severity following AVR ranged from 17.2% to 72%; the studies that exclusively included patients with moderate functional MR and reported longer term echocardiographic follow-up of greater than 12 months demonstrated an improvement in MR severity of 45% to 72%. Conclusion: This systematic review demonstrates that a proportion of patients can exhibit an improvement in MR following isolated surgical AVR, but whether this confers any long-term morbidity and mortality benefit remains unclear.","PeriodicalId":8037,"journal":{"name":"Annals of Thoracic and Cardiovascular Surgery","volume":"28 3","pages":"214-222"},"PeriodicalIF":1.3,"publicationDate":"2022-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/af/26/atcs-28-214.PMC9209887.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39901210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A Blinded Randomized Trial Comparing Standard Activated Clotting Time Heparin Management to High Target Active Clotting Time and Individualized Hepcon HMS Heparin Management in Cardiopulmonary Bypass Cardiac Surgical Patients. 一项比较体外循环心脏手术患者标准活化凝血时间肝素管理与高目标活化凝血时间和个体化Hepcon HMS肝素管理的随机盲法试验。
IF 1.3 4区 医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2022-06-20 Epub Date: 2021-12-22 DOI: 10.5761/atcs.oa.21-00222
Gregory A Nuttall, Mark M Smith, Bradford B Smith, Jon M Christensen, Paula J Santrach, Hartzell V Schaff

Purpose: High-dose heparin has been suggested to reduce consumption coagulopathy.

Materials and methods: In a randomized, blinded, prospective trial of patients undergoing elective, complex cardiac surgery with cardiopulmonary bypass, patients were randomized to one of three groups: 1) high-dose heparin (HH) receiving an initial heparin dose of 450 u/kg, 2) heparin concentration monitoring (HC) with Hepcon Hemostasis Management System (HMS; Medtronic, Minneapolis, MN, USA) monitoring, or 3) a control group (C) receiving a standard heparin dose of 300 u/kg. Primary outcome measures were blood loss and transfusion requirements.

Results: There were 269 patients block randomized based on primary versus redo sternotomy to one of the three groups from August 2001 to August 2003. There was no difference in operative bleeding between the groups. Chest tube drainage did not differ between treatment groups at 8 hours (median [25th percentile, 75th percentile] for control group was 321 [211, 490] compared to 340 [210, 443] and 327 [250, 545], p = 0.998 and p = 0.540, for HH and HC treatment groups, respectively). The percentage of patients receiving transfusion was not different among the groups.

Conclusion: Higher heparin dosing accomplished by either activated clot time or HC monitoring did not reduce 24-hour intensive care unit blood loss or transfusion requirements.

目的:大剂量肝素已被建议用于减少消耗性凝血病。材料与方法:在一项随机、盲法、前瞻性试验中,接受选择性复杂心脏手术合并体外循环的患者,患者被随机分为三组:1)高剂量肝素(HH),初始肝素剂量为450 u/kg, 2)肝素浓度监测(HC)使用Hepcon止血管理系统(HMS);Medtronic, Minneapolis, MN, USA)监测,或3)对照组(C)接受300u /kg标准肝素剂量。主要结局指标为失血量和输血需求。结果:2001年8月至2003年8月,269例患者根据首次胸骨切开术和再次胸骨切开术进行分组随机。两组手术出血无明显差异。治疗组间8小时胸管引流无差异(对照组[25、75百分位数]中位数为321[211、490],HH组为340[210、443],HC组为327[250、545],p = 0.998和p = 0.540)。两组患者接受输血的比例没有差异。结论:通过活化凝块时间或HC监测实现的高肝素剂量并没有减少24小时重症监护病房的出血量或输血需求。
{"title":"A Blinded Randomized Trial Comparing Standard Activated Clotting Time Heparin Management to High Target Active Clotting Time and Individualized Hepcon HMS Heparin Management in Cardiopulmonary Bypass Cardiac Surgical Patients.","authors":"Gregory A Nuttall,&nbsp;Mark M Smith,&nbsp;Bradford B Smith,&nbsp;Jon M Christensen,&nbsp;Paula J Santrach,&nbsp;Hartzell V Schaff","doi":"10.5761/atcs.oa.21-00222","DOIUrl":"https://doi.org/10.5761/atcs.oa.21-00222","url":null,"abstract":"<p><strong>Purpose: </strong>High-dose heparin has been suggested to reduce consumption coagulopathy.</p><p><strong>Materials and methods: </strong>In a randomized, blinded, prospective trial of patients undergoing elective, complex cardiac surgery with cardiopulmonary bypass, patients were randomized to one of three groups: 1) high-dose heparin (HH) receiving an initial heparin dose of 450 u/kg, 2) heparin concentration monitoring (HC) with Hepcon Hemostasis Management System (HMS; Medtronic, Minneapolis, MN, USA) monitoring, or 3) a control group (C) receiving a standard heparin dose of 300 u/kg. Primary outcome measures were blood loss and transfusion requirements.</p><p><strong>Results: </strong>There were 269 patients block randomized based on primary versus redo sternotomy to one of the three groups from August 2001 to August 2003. There was no difference in operative bleeding between the groups. Chest tube drainage did not differ between treatment groups at 8 hours (median [25th percentile, 75th percentile] for control group was 321 [211, 490] compared to 340 [210, 443] and 327 [250, 545], p = 0.998 and p = 0.540, for HH and HC treatment groups, respectively). The percentage of patients receiving transfusion was not different among the groups.</p><p><strong>Conclusion: </strong>Higher heparin dosing accomplished by either activated clot time or HC monitoring did not reduce 24-hour intensive care unit blood loss or transfusion requirements.</p>","PeriodicalId":8037,"journal":{"name":"Annals of Thoracic and Cardiovascular Surgery","volume":"28 3","pages":"204-213"},"PeriodicalIF":1.3,"publicationDate":"2022-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6b/6f/atcs-28-204.PMC9209891.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39747604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Comprehensive Pain Control Strategy in Minimally Invasive Mitral Valve Repair. 微创二尖瓣修复的综合疼痛控制策略。
IF 1.3 4区 医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2022-06-20 Epub Date: 2021-12-07 DOI: 10.5761/atcs.oa.21-00131
Mitsuharu Hosono, Hiroshi Yasumoto, Shintaro Kuwauchi, Yoshino Mitsunaga, Uetsuki Tomohiko, Naoki Minato, Kohei Kawazoe

Purpose: The effect of our comprehensive strategy to reduce pain after minimally invasive mitral valve repair through a right mini-thoracotomy was assessed retrospectively.

Methods: Our comprehensive strategy constituted the following: planned rib cutting to avoid rib injury, sufficient intercostal muscle division to mobilize the cut rib, limiting the number of intercostal ports, avoiding nerve entrapment, continuous extra-pleural intercostal nerve block, and regular use of oral non-steroidal anti-inflammatory drugs. We compared patients treated with this comprehensive strategy (Group S, n = 13) and patients before this strategy was implemented (Group C, n = 13). We used a numerical rating scale (NRS) as a pain scale during the first 3 days postoperatively.

Results: The average NRS was significantly lower in Group S (0.82 ± 0.49) than in Group C (2.40 ± 1.46) (P <0.01). The maximum NRS was also significantly lower in Group S (3.23 ± 1.17) than in Group C (5.69 ± 2.43) (P <0.01). The number of patients using additional single-dose analgesic were significantly less in Group S (23.1%) than in Group C (84.6%) (P <0.01).

Conclusion: Our comprehensive pain control strategy effectively reduced postoperative pain in minimally invasive mitral valve repair.

目的:回顾性评价经右小开胸微创二尖瓣修复术后综合治疗方案的效果。方法:我们的综合策略是:有计划的肋骨切割以避免肋骨损伤,充分的肋间肌分隔以调动被切割的肋骨,限制肋间端口的数量,避免神经卡压,持续的胸膜外肋间神经阻滞,定期使用口服非甾体类抗炎药。我们比较采用该综合策略治疗的患者(S组,n = 13)和未采用该策略的患者(C组,n = 13)。我们使用数值评定量表(NRS)作为术后前3天的疼痛量表。结果:S组的平均NRS(0.82±0.49)明显低于C组(2.40±1.46)(P)。结论:综合疼痛控制策略可有效减轻微创二尖瓣修复术后的疼痛。
{"title":"Comprehensive Pain Control Strategy in Minimally Invasive Mitral Valve Repair.","authors":"Mitsuharu Hosono,&nbsp;Hiroshi Yasumoto,&nbsp;Shintaro Kuwauchi,&nbsp;Yoshino Mitsunaga,&nbsp;Uetsuki Tomohiko,&nbsp;Naoki Minato,&nbsp;Kohei Kawazoe","doi":"10.5761/atcs.oa.21-00131","DOIUrl":"https://doi.org/10.5761/atcs.oa.21-00131","url":null,"abstract":"<p><strong>Purpose: </strong>The effect of our comprehensive strategy to reduce pain after minimally invasive mitral valve repair through a right mini-thoracotomy was assessed retrospectively.</p><p><strong>Methods: </strong>Our comprehensive strategy constituted the following: planned rib cutting to avoid rib injury, sufficient intercostal muscle division to mobilize the cut rib, limiting the number of intercostal ports, avoiding nerve entrapment, continuous extra-pleural intercostal nerve block, and regular use of oral non-steroidal anti-inflammatory drugs. We compared patients treated with this comprehensive strategy (Group S, n = 13) and patients before this strategy was implemented (Group C, n = 13). We used a numerical rating scale (NRS) as a pain scale during the first 3 days postoperatively.</p><p><strong>Results: </strong>The average NRS was significantly lower in Group S (0.82 ± 0.49) than in Group C (2.40 ± 1.46) (P <0.01). The maximum NRS was also significantly lower in Group S (3.23 ± 1.17) than in Group C (5.69 ± 2.43) (P <0.01). The number of patients using additional single-dose analgesic were significantly less in Group S (23.1%) than in Group C (84.6%) (P <0.01).</p><p><strong>Conclusion: </strong>Our comprehensive pain control strategy effectively reduced postoperative pain in minimally invasive mitral valve repair.</p>","PeriodicalId":8037,"journal":{"name":"Annals of Thoracic and Cardiovascular Surgery","volume":"28 3","pages":"180-185"},"PeriodicalIF":1.3,"publicationDate":"2022-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b8/55/atcs-28-180.PMC9209889.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39816591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Bailout Solution for Hemostasis from Distal Anastomotic Site during Total Aortic Arch Repair. 全主动脉弓修复术中吻合口远端止血的救助方法。
IF 1.3 4区 医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2022-06-20 Epub Date: 2021-12-16 DOI: 10.5761/atcs.nm.21-00228
Takashi Yamauchi

Intraoperative bleeding from the distal anastomotic site during graft replacement of the arch to distal arch via median sternotomy to treat an aortic aneurysm is sometimes difficult to control because of the limited distal view. I herein report a case in which I addressed this uncontrollable bleeding using a commercialized frozen elephant trunk.

由于远端视野有限,经胸骨正中切口将弓移植物置换至远端弓治疗主动脉瘤时,术中远端吻合口出血有时难以控制。我在此报告一个案例,我使用商业化的冷冻象鼻来解决这种无法控制的出血。
{"title":"Bailout Solution for Hemostasis from Distal Anastomotic Site during Total Aortic Arch Repair.","authors":"Takashi Yamauchi","doi":"10.5761/atcs.nm.21-00228","DOIUrl":"https://doi.org/10.5761/atcs.nm.21-00228","url":null,"abstract":"<p><p>Intraoperative bleeding from the distal anastomotic site during graft replacement of the arch to distal arch via median sternotomy to treat an aortic aneurysm is sometimes difficult to control because of the limited distal view. I herein report a case in which I addressed this uncontrollable bleeding using a commercialized frozen elephant trunk.</p>","PeriodicalId":8037,"journal":{"name":"Annals of Thoracic and Cardiovascular Surgery","volume":"28 3","pages":"236-238"},"PeriodicalIF":1.3,"publicationDate":"2022-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/85/0d/atcs-28-236.PMC9209892.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39728571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resection of Pulmonary Metastases 12 Years after Initial Surgery for a Benign Pheochromocytoma. 良性嗜铬细胞瘤初次手术12年后肺转移瘤的切除。
IF 1.3 4区 医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2022-06-20 Epub Date: 2020-10-16 DOI: 10.5761/atcs.cr.20-00162
Michiko Ueda, Fumihiro Shoji, Yuka Kozuma, Gouji Toyokawa, Koji Yamazaki, Seiya Momosaki, Sadanori Takeo

We describe a rare case of newly discovered pulmonary metastases and surgical confirmation 12 years after initial surgery for a pheochromocytoma. A 61-year-old asymptomatic man was referred because of an abnormal shadow in the right lung field upon chest radiography. Computed tomography (CT) showed two well-demarcated tumors in the basal segment of the right lung. Twelve years previously, he underwent right adrenalectomy and was pathologically diagnosed as having a benign pheochromocytoma. Thereafter, he received a medical check-up annually. To confirm the diagnosis of two pulmonary tumors, video-assisted thoracic surgery was done and wedge resection of the right lower lobe completed. Pathology studies revealed these tumors as pulmonary metastases from the pheochromocytoma, which indicated that the true diagnosis was a malignant pheochromocytoma. Patients with a benign pheochromocytoma should continue to undergo careful monitoring for a long time after the initial surgical procedure. Thoracic surgeons should be aware of the possibility of pulmonary metastases even if >10 years have passed since initial resection of a benign pheochromocytoma.

我们描述一个罕见的病例新发现的肺转移和手术确认12年后首次手术后的嗜铬细胞瘤。一位61岁无症状男性,因胸片右肺野异常影而被转介。计算机断层扫描(CT)显示右肺基底段有两个界限清楚的肿瘤。12年前,他接受了右肾上腺切除术,病理诊断为良性嗜铬细胞瘤。此后,他每年接受一次体检。为了确认两例肺部肿瘤的诊断,我们进行了胸腔镜手术,并完成了右下肺叶楔形切除术。病理检查显示这些肿瘤为嗜铬细胞瘤的肺转移瘤,这表明真正的诊断是恶性嗜铬细胞瘤。良性嗜铬细胞瘤患者在初次手术后应继续进行长时间的仔细监测。胸外科医生应该意识到肺转移的可能性,即使良性嗜铬细胞瘤最初切除>10年。
{"title":"Resection of Pulmonary Metastases 12 Years after Initial Surgery for a Benign Pheochromocytoma.","authors":"Michiko Ueda,&nbsp;Fumihiro Shoji,&nbsp;Yuka Kozuma,&nbsp;Gouji Toyokawa,&nbsp;Koji Yamazaki,&nbsp;Seiya Momosaki,&nbsp;Sadanori Takeo","doi":"10.5761/atcs.cr.20-00162","DOIUrl":"https://doi.org/10.5761/atcs.cr.20-00162","url":null,"abstract":"<p><p>We describe a rare case of newly discovered pulmonary metastases and surgical confirmation 12 years after initial surgery for a pheochromocytoma. A 61-year-old asymptomatic man was referred because of an abnormal shadow in the right lung field upon chest radiography. Computed tomography (CT) showed two well-demarcated tumors in the basal segment of the right lung. Twelve years previously, he underwent right adrenalectomy and was pathologically diagnosed as having a benign pheochromocytoma. Thereafter, he received a medical check-up annually. To confirm the diagnosis of two pulmonary tumors, video-assisted thoracic surgery was done and wedge resection of the right lower lobe completed. Pathology studies revealed these tumors as pulmonary metastases from the pheochromocytoma, which indicated that the true diagnosis was a malignant pheochromocytoma. Patients with a benign pheochromocytoma should continue to undergo careful monitoring for a long time after the initial surgical procedure. Thoracic surgeons should be aware of the possibility of pulmonary metastases even if >10 years have passed since initial resection of a benign pheochromocytoma.</p>","PeriodicalId":8037,"journal":{"name":"Annals of Thoracic and Cardiovascular Surgery","volume":"28 3","pages":"232-235"},"PeriodicalIF":1.3,"publicationDate":"2022-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d2/66/atcs-28-232.PMC9209893.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38506863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Annals of Thoracic and Cardiovascular Surgery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1